Table 3.
Age distribution and treatment regimens in reports of elderly APL patients
| Author (year) [reference] | Number of patients | Median age (range) | High risk (%) | Age ≥70 years (%) | Induction regimen | Consolidation cycles | Maintenance |
|---|---|---|---|---|---|---|---|
| Mandelli (2005) [31] | 134 | 66 (60–75) | – | 14 | ATRA + Ida | 1–3 | Yes |
| Sanz (2004) [32] | 104 | 68 (60–83) | 20 | 33 | ATRA + Ida | 3 | Yes |
| Ades (2005) [33] | 129 | 66 (62–70) | – | 0 | ATRA + AD | 1–2 | Yes |
| Lataglia (2010) [34] | 60 | 66 (60–73) | 14 | – | ATRA + Ida | 1 | Yes |
| Ono (2011) [35] | 46 | 63 (60–70) | 20 | 0 | ATRA + Ida + Ara-C | 3 | Yes |
| Lengfelder (2013) [23] | 56 | 67 (60–83) | 32 | 32 | ATRA + TAD (±HAM) | 1 | Yes |
ATRA all-trans retinoic acid, Ida idarubicin, ara-C cytosine arabinoside, AD ara-C daunorubicin, TAD 6-thioguanine ara-C daunorubicin, HAM high-dose ara-C mitoxantrone